Key result
Adding thrombotic and thrombolytic biomarkers to CHA2DS2-VASc improves incident stroke prediction by ~0.01 C-index.
Why the study?
Measuring the balance between thrombus formation and thrombolysis and its role in predicting incident stroke and AF-related stroke is limited.
Does the assessment of composite thrombotic and thrombolytic biomarker factors improve risk prediction for incident stroke or TIA in adults free of baseline cardiovascular disease?
Cohort (n=5,764)
Yes
Does the assessment of composite thrombotic and thrombolytic biomarker factors improve risk prediction for incident stroke or TIA in adults free of baseline cardiovascular disease?
Composite circulating biomarker factors reflecting the balance between thrombotic and thrombolytic propensity modestly improve the prediction of incident and AF-related stroke/TIA beyond the standard CHA2DS2-VASc score.
Answers are grounded in this paper and cite their sources.
May modestly refine CHA2DS2-VASc stroke prediction; hypothesis-generating and requires validation before clinical adoption.
Background and aims Although several biomarkers have been studied in thromboembolic stroke, measuring the balance between thrombus formation and thrombolysis and its role in predicting stroke and atrial fibrillation (AF)-related stroke is limited. We sought to assess atherothrombotic biomarkers grouped into composite factors that reflect thrombotic and thrombolytic potential, and the balance between these factors as it relates to incident stroke or transient ischemic attack (TIA) and stroke/TIA in AF. Methods A Thrombotic Factor , derived from fibrinogen, plasmin–antiplasmin complex, factor VIII, D-dimer, and lipoprotein(a); and a Thrombolytic Factor , derived from plasminogen and oxidized phospholipids on plasminogen, were evaluated at baseline in 5,764 Multi-Ethnic Study of Atherosclerosis (MESA) participants. We evaluated the association between these two factors representative of thrombotic and thrombolytic potential and incident stroke/TIA (n = 402), and AF-related stroke/TIA (n = 82) over a median of 13.9 and 3.7 years, respectively. Cox proportional hazard models adjusted for medication use, cardiovascular risk factors and CHA 2 DS 2 -VASc score were utilized. Harrell's C-index was estimated to evaluate model performance. Results In models including both factors, Thrombotic Factor was positively while Thrombolytic Factor was inversely associated with incident stroke/TIA and AF-related stroke/TIA. Incorporating these factors along with the CHA 2 DS 2 -VASc in adjusted models resulted in a small improvement in risk prediction of incident stroke/TIA and AF-related stroke/TIA compared to models without the factors (C-index from 0.697 to 0.704, and from 0.657 to 0.675, respectively). Conclusions Composite biomarker factors, representative of the balance between thrombotic and thrombolytic propensity, provided an improvement in predicting stroke/TIA beyond CHA 2 DS 2 -VASc score.
No takes yet. Share an insight, caveat, or question.
Lidani et al. (2024) conducted a cohort in Incident stroke/TIA and AF-related stroke/TIA (n=5,764). Composite atherothrombotic biomarkers (Thrombotic Factor and Thrombolytic Factor) vs. CHA2DS2-VASc score alone (without biomarker factors) was evaluated on Incident stroke or transient ischemic attack (TIA) (C-index improvement from 0.697 to 0.704, p=<0.001). The addition of composite thrombotic and thrombolytic biomarker factors to the CHA2DS2-VASc score improved risk prediction for incident stroke/TIA.
Synapse has enriched 10 related papers. Consider them for comparative context: